Our results suggest that, in specific conditions, Chk2 activation at Thr68 phosphorylation is regulated by p53 in response to cisplatin treatment in wt p53-contain cells, but not in p53-deficient cells, of human ovarian cancer. The gene discussed is TP53; the disease is ovarian carcinoma.